Safety and Immunogenicity Study of the HPV Vaccine (GSK-580299) [human papillomavirus vaccine MEDI-517] in Healthy, Chinese, Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 18 Apr 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Feb 2008 The expected completion date for this trial is now 1 Aug 2008 as reported by ClinicalTrials.gov.